- Company
- K-similars won record number of U.S.·Europe nods this year
- by Chon, Seung-Hyun Aug 27, 2024 05:50am
- Korean biopharmaceutical companies have launched the highest number of biosimilars in history this year in the United States and European markets. As Celltrion and Samsung Bioepis won approvals for six biosimilars over eight months in the world's largest market, they topped the previous record of five cases of five years ago. According to sou
- Policy
- SK Chemicals strengthens migraine drug lineup with Suvexx
- by Lee, Tak-Sun Aug 27, 2024 05:50am
- Suvexx, a combination migraine treatment imported and supplied by SK Chemicals, will be reimbursed in Korea next month. Suvexx is a combination of sumatriptan, a triptan-class drug most commonly used for migraine, and naproxen, a non-steroidal anti-inflammatory drug (NSAID). According to industry sources on the 26th, Suvexx will be lis
- InterView
- AstraZeneca seeks mutual growth through open collaboration
- by Hwang, Byung-woo Aug 27, 2024 05:50am
- Multinational pharmaceutical companies are increasingly investing in R&D in Korea’s domestic pharmaceutical industry through open innovation. According to the Korean Research-based Pharmaceutical Industry Association (KRPIA), the total amount of R&D invested in clinical research in Korea in 2022 was KRW 817.8 billion and has been on t
- Company
- More urothelial cancer drug options now available in KOR
- by Hwang, Byung-woo Aug 26, 2024 05:46am
- A number of immuno-oncology and antibody-drug conjugate (ADC) drugs are being granted approval as a first-line treatment of urothelial cancer, increasing the treatment options that had previously been dominated by platinum-based chemotherapy. Although they are not yet reimbursed and have yet to become mainstream treatment options, it is expe
- Company
- ‘Lilly will reapply for Retevmo’s reimbursement in Korea’
- by Eo, Yun-Ho Aug 26, 2024 05:46am
- “We will do our best to receive reimbursement for Retevmo in Korea. However, the will of the health authorities is as important” The company has expressed its will to list a RET-targeted therapy option in Korea. The question that remains now is when. Lilly's RET inhibitor Retevmo (selpercatinib) remains non-reimbursed since the compa
- Policy
- Eliquis generics re-enter the market, 35 reimbursed drugs
- by Lee, Tak-Sun Aug 26, 2024 05:46am
- Drugs that are generic versions of the coagulant agent Eliquis (apixaban) will re-enter the market three and five months after discontinuing sales due to a failing patent nullification challenge. It is because the original drug's substance patent is set to expire on September 9th. According to sources on August 23rd, generics containi
- Company
- Colorectal cancer drug Fruzaqla may be introduced in H2
- by Eo, Yun-Ho Aug 26, 2024 05:46am
- A new treatment option is expected to emerge in the field of colorectal cancer later this year. According to industry sources, the final review is underway for the approval of Fruzaqla (fruquintinib), which was designated as a Global Innovative products on Fast Track (GIFT) by the Ministry of Food and Drug Safety in November last year.
- Policy
- Hanmi faces competition from cheaper Zytiga generic drug
- by Lee, Tak-Sun Aug 26, 2024 05:45am
- A new competing drug has entered the 'Zytiga' generic market, where Hanmi Pharmaceutical was the only company to launch a product last year. Ace Pharmaceutical has introduced a drug imported from India to the South Korean market. While Hanmi Pharmaceutical is strengthening its market presence by recently launching a combination drug
- Company
- Expansion of newly launched Kerendia underway in KOR
- by Moon, sung-ho Aug 23, 2024 06:18am
- Since early this year, Kerendia has been covered by reimbursement in clinical practices in South Korea. Kerendia's indication may expand to hypertension as it becomes available for prescriptions at clinical practices. According to the pharmaceutical industry on August 13th, Kerendia (finerenone) is now being used in clinical practices
- Opinion
- [Reporter’s View]Gov’t disappointing response to COVID-19
- by Son, Hyung-Min Aug 23, 2024 06:18am
- COVID-19 is spreading rapidly in Korea. Currently, the variant leading the COVID-19 pandemic is KP.3 of the Omicron family. The spread of COVID-19 has been in full swing since the end of June, and the number of hospitalized patients in the 2nd week of this month reached 1,366, recording the highest this year. In the last four weeks, the n
